Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2024)
Avalo Therapeutics posted quarterly Change in Receivables of -$387000.0 for Q4 2024, up 72.4% year-on-year from -$224482.4 in Q1 2024, and down 140.1% on a QoQ basis from $965000.0 in Q3 2024.
Avalo Therapeutics (AVTX) has 8 years of Change in Receivables data on file, last reported at -$387000.0 in Q4 2024.
- For the quarter ending Q4 2024, Change in Receivables rose 72.4% year-over-year to -$387000.0; the trailing twelve-month figure through Dec 2024 stood at $475000.0 (up 126.64% YoY), and the FY2024 full-year result was $475000.0, up 126.64% from the prior year.
- Change in Receivables for Q4 2024 stood at -$387000.0, down from $965000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $3.7 million in Q3 2020 and bottomed at -$2.7 million in Q3 2021.
- The 5-year median for Change in Receivables is -$112000.0 (2022), against an average of $63500.0.
- Peak annual rise in Change in Receivables reached 1022.33% in 2020, while the deepest fall reached 1577.66% in 2020.
- A 5-year view of Change in Receivables shows it stood at -$2.1 million in 2020, then soared by 209.44% to $2.3 million in 2021, then sank by 39.95% to $1.4 million in 2022, then sank by 202.71% to -$1.4 million in 2023, then jumped by 72.4% to -$387000.0 in 2024.
- The last three Change in Receivables figures came in at -$387000.0 (Q4 2024), $965000.0 (Q3 2024), and -$2000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -387,000.00 |
| Dec 31, 2024 | -387,000.00 |
| Sep 30, 2024 | 965,000.00 |
| Sep 30, 2024 | 965,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -101,000.00 |
| Mar 31, 2024 | -101,000.00 |
| Dec 31, 2023 | -1.40 Mn |
| Dec 31, 2023 | -1.40 Mn |
| Sep 30, 2023 | -419,000.00 |
| Sep 30, 2023 | -419,000.00 |
| Jun 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | -1.06 Mn |
| Mar 31, 2023 | -1.06 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | -1.91 Mn |
| Sep 30, 2022 | -1.91 Mn |
| Jun 30, 2022 | -393,000.00 |
| Jun 30, 2022 | -393,000.00 |
| Mar 31, 2022 | -123,000.00 |
| Mar 31, 2022 | -123,000.00 |
| Dec 31, 2021 | 2.27 Mn |
| Dec 31, 2021 | 2.27 Mn |
| Sep 30, 2021 | -2.69 Mn |
| Sep 30, 2021 | -2.69 Mn |
| Jun 30, 2021 | 990,000.00 |
| Jun 30, 2021 | 990,000.00 |
| Mar 31, 2021 | 953,000.00 |
| Mar 31, 2021 | 953,000.00 |
| Dec 31, 2020 | -2.08 Mn |
| Dec 31, 2020 | -2.08 Mn |
| Sep 30, 2020 | 3.65 Mn |
| Sep 30, 2020 | 3.65 Mn |
| Jun 30, 2020 | -164,000.00 |
| Jun 30, 2020 | -164,000.00 |
| Mar 31, 2020 | 696,000.00 |
| Mar 31, 2020 | 696,000.00 |
| Dec 31, 2019 | 140,560.00 |
| Dec 31, 2019 | 140,560.00 |
| Sep 30, 2019 | -4.96 Mn |
| Sep 30, 2019 | -4.96 Mn |
| Jun 30, 2019 | -359,281.00 |
| Jun 30, 2019 | -359,281.00 |
| Mar 31, 2019 | 62,014.00 |
| Mar 31, 2019 | 62,014.00 |
| Dec 31, 2018 | -795,474.00 |
| Dec 31, 2018 | -795,474.00 |
| Sep 30, 2018 | 2.70 Mn |
| Sep 30, 2018 | 2.70 Mn |
| Jun 30, 2018 | 744,962.00 |
| Jun 30, 2018 | 744,962.00 |
| Mar 31, 2018 | -371,663.00 |
| Mar 31, 2018 | -371,663.00 |
| Dec 31, 2017 | 427,241.00 |
| Dec 31, 2017 | 427,241.00 |